Pressure BioSciences Announces Approval to Manufacture Hemp-Derived CBD Products in Massachusetts, Including Their Revolutionary CBD Nanoemulsions
Canopy CBD Farms, MA-licensed North American Processor/Manufacturer/Distributor of CBD Products Derived from Hemp, Received State Approval Covering PBI’s Manufacture of CBD Nanoemulsions for Sale to MA and Nationwide Formulators and Manufacturers of Hemp-Derived CBD Products
SOUTH EASTON, MA / ACCESSWIRE / August 11, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide biopharmaceuticals, nutraceuticals, cosmetics, agrochemical, and food & beverage industries, today announced approval for its South Easton MA facility to manufacture custom, compliant, hemp-derived CBD nanoemulsions under the processing/manufacturing license of its commercial partner, Canopy CBD Farms, Fitchburg, MA.
Canopy CBD Farms (“CCF”) is a Massachusetts licensed hemp processing and manufacturing company. Foreseeing the future of government regulations, CCF has strategically aligned itself with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD Farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. CCF’s partnerships will increase wholesale and retail distribution channels, with a ready-to-label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.
Mr. John Westlake, Founder and President of CCF, commented, “I am delighted to partner with PBI by extending my CBD processing and manufacturing license to PBI’s South Easton location. I firmly believe I can leverage my many years in the cannabis market and hundreds of industry connections to help PBI get quickly and efficiently to market with their unique, highly stable, and water-soluble hemp-derived CBD nanoemulsions, processed using their world-class UST platform.”
Using the Company’s patented Ultra Shear Technology™ (“UST™”) platform, PBI will manufacture and sell – through a tolling processing center located in their South Easton MA facility – a new generation of effectively water-soluble hemp-derived CBD nanoemulsions, in bulk format. Expected to be purchased primarily by formulators and manufacturers, both in MA and throughout the U.S., PBI’s nano-CBD is expected to introduce revolutionary precise and efficient dosing of hemp-derived, nanoemulsified CBD in a wide variety of shelf-stable, clean-label (containing no chemical preservatives) products, encompassing the nutraceuticals, personal care products, cosmetics, and food/beverage markets, to name a few.
Mr. Kenneth F. Micciche, Director of Business Development at PBI, stated: “We are thrilled that our facility has been inspected and approved by the Mass. Dept. of Agricultural Resources (“MDAR”). We can now begin a new phase for our business, to produce and deliver the finest available water-soluble hemp-derived CBD nanoemulsions for use in thousands of products, in MA and throughout the U.S. We believe our nano-CBD will deliver unprecedented up-take, quality, potency, and reliable dosage control and delivery. CCF’s MDAR license – required to process hemp-derived CBD in MA – enables PBI to begin to fulfill the customer demand and signed production contracts that we previously announced, and the many new ones to come, for the highest quality CBD nanoemulsions in a global market estimated to reach $16.6 billion by 2027.”
Mr. Richard T. Schumacher, President and CEO of PBI summarized: “We believe our UST technology platform, coupled with CCF’s license to process/manufacture in MA and John’s impressive experience and remarkable contacts in the cannabis field, will greatly support the launch of our tolling service model, driven by the delivery of high value, UST-processed CBD nanoemulsion products that provide an improved experience derived from enhanced quality and bioavailability.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President & CEO (508) 230-1828 (T)
John B. Hollister, Director Sales and Marketing (805) 908-5719 (T)
Kenneth F. Micciche Director Business Development (508) 230-1828(T)
John Westlake, President & Founder, Canopy CBD Farms, LLC. (978) 471-9981 (T)
SOURCE: Pressure BioSciences Inc.